NCT05167994

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）

Preoperative Intensity-modulated Radiotherapy (IMRT) With Concurrent Anlotinib Hydrochloride for Localised Extremity or Trunk Sarcoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.

Conditions

• Sarcoma,Soft Tissue
• Extremity
• Trunk
• Anlotinib
• Intensity-modulated Radiotherapy
• Major Wound Complications

Interventions

Type	Name	Description
DRUG	Anlotinib hydrochloride	Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT

Timeline

• Start date: 2020-05-01
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2021-12-22
• Last updated: 2025-12-11

Locations

1 site across 1 country: China